No Data
Zhejiang Huahai Pharmaceutical Secures Clinical Trial Approval for Asthma Treatment
Zhejiang Huahai Pharmaceutical (600521.SH): HB0056 injection solution has been approved to conduct Phase I clinical trials in New Zealand.
Zhejiang Huahai Pharmaceutical (600521.SH) released an announcement, its subsidiary Shanghai Huao Tai Biopharmaceutical Co., Ltd...
Huahai Pharmaceutical: Zhejiang Huahai Pharmaceutical Co., Ltd. Third Quarter Report 2024
Zhejiang Huahai Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024
Ping An Securities: The supply and demand relationship of active pharmaceutical ingredients continues to improve, and the integration of formulations contributes to long-term growth.
According to IQVIA data, from 2024 to 2028, the global pharmaceutical sales facing patent cliffs and losses are approximately $192 billion, presenting a development opportunity for generic drugs and related specialty active pharmaceutical ingredient companies.
Huahai Pharmaceutical Gets Nod to Register Argatroban Injection; Shares Up 4%
Earnings Are Growing at Zhejiang Huahai Pharmaceutical (SHSE:600521) but Shareholders Still Don't Like Its ProspectsNo Data
No Data
